259 related articles for article (PubMed ID: 26092960)
41. Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes.
Trujillo JM; Goldman J
Pharmacotherapy; 2017 Aug; 37(8):927-943. PubMed ID: 28556176
[TBL] [Abstract][Full Text] [Related]
42. Gastrointestinal safety across the albiglutide development programme.
Leiter LA; Mallory JM; Wilson TH; Reinhardt RR
Diabetes Obes Metab; 2016 Sep; 18(9):930-5. PubMed ID: 27097971
[TBL] [Abstract][Full Text] [Related]
43. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
Isaacs D; Prasad-Reddy L; Srivastava SB
Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
[TBL] [Abstract][Full Text] [Related]
44. Once-weekly glucagon-like peptide 1 receptor agonists.
Kalra S; Gupta Y
J Pak Med Assoc; 2015 Jul; 65(7):796-8. PubMed ID: 26160096
[TBL] [Abstract][Full Text] [Related]
45. Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis.
Fisher M; Petrie MC; Ambery PD; Donaldson J; Ye J; McMurray JJ
Lancet Diabetes Endocrinol; 2015 Sep; 3(9):697-703. PubMed ID: 26276240
[TBL] [Abstract][Full Text] [Related]
46. Liraglutide: a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus.
Joffe D
Am J Health Syst Pharm; 2010 Aug; 67(16):1326-36. PubMed ID: 20689121
[TBL] [Abstract][Full Text] [Related]
47. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.
Monami M; Marchionni N; Mannucci E
Eur J Endocrinol; 2009 Jun; 160(6):909-17. PubMed ID: 19318378
[TBL] [Abstract][Full Text] [Related]
48. A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus.
Seino Y; Inagaki N; Miyahara H; Okuda I; Bush M; Ye J; Holland MC; Johnson S; Lewis E; Nakajima H
Curr Med Res Opin; 2014 Jun; 30(6):1095-106. PubMed ID: 24552155
[TBL] [Abstract][Full Text] [Related]
49. Liraglutide: a review of its use in the management of type 2 diabetes mellitus.
Perry CM
Drugs; 2011 Dec; 71(17):2347-73. PubMed ID: 22085389
[TBL] [Abstract][Full Text] [Related]
50. Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.
Guo X; Yang Q; Dong J; Liao L; Zhang W; Liu F
Clin Drug Investig; 2016 Jun; 36(6):433-41. PubMed ID: 26979594
[TBL] [Abstract][Full Text] [Related]
51. Effect of Albiglutide on Cholecystokinin-Induced Gallbladder Emptying in Healthy Individuals: A Randomized Crossover Study.
Shaddinger BC; Young MA; Billiard J; Collins DA; Hussaini A; Nino A
J Clin Pharmacol; 2017 Oct; 57(10):1322-1329. PubMed ID: 28543352
[TBL] [Abstract][Full Text] [Related]
52. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.
Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
Diabetes Res Clin Pract; 2014 Feb; 103(2):269-75. PubMed ID: 24485345
[TBL] [Abstract][Full Text] [Related]
53. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
Ryan GJ; Hardy Y
J Clin Pharm Ther; 2011 Jun; 36(3):260-74. PubMed ID: 21545609
[TBL] [Abstract][Full Text] [Related]
54. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
55. Next-generation GLP-1 therapy: an introduction to liraglutide.
Repas T
Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
[TBL] [Abstract][Full Text] [Related]
56. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders.
Wroge J; Williams NT
Ann Pharmacother; 2016 Dec; 50(12):1041-1050. PubMed ID: 27531946
[TBL] [Abstract][Full Text] [Related]
57. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
[TBL] [Abstract][Full Text] [Related]
58. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
Doggrell SA
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):371-377. PubMed ID: 29439603
[TBL] [Abstract][Full Text] [Related]
59. Albiglutide: Is a better hope against diabetes mellitus?
Sharma AK; Thanikachalam PV; Rajput SK
Biomed Pharmacother; 2016 Feb; 77():120-8. PubMed ID: 26796275
[TBL] [Abstract][Full Text] [Related]
60. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Drucker DJ; Nauck MA
Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]